PCM
WPF.WS

Poehling Capital Management’s Foley Trasimene Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A WPF.WS Stock Holding History

Poehling Capital Management’s Portfolio WPF.WS Stock Details WPF.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-915,903
Closed -$1.91M – 154
2021
Q2 		$1.91M Buy
915,903
+1,259
+0.1% +$2.25K 0.61% 58
2021
Q1 		$1.46M Buy
914,644
+9,943
+1% +$22K 0.51% 68
2020
Q4 		$2.29M Buy
+904,701
New +$1.71M 0.91% 44

Poehling Capital Management's WPF.WS Position: Q3 2021 in Review

Poehling Capital Management sold out of Foley Trasimene Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A (WPF.WS) in Q3 2021, closing a stake of 915,903 shares — an estimated $1.91M sold.

Poehling Capital Management first reported a position in WPF.WS in Q4 2020 and held it in 3 quarters. The position peaked at $2.29M in Q4 2020. 0 funds tracked by Wall St. Rank hold WPF.WS as of Q3 2021.

  • Poehling Capital Management reported no remaining Foley Trasimene Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A position as of Q3 2021 after selling out during the quarter.
  • Poehling Capital Management sold 915,903 Foley Trasimene Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A shares in Q3 2021, an estimated $1.91M.
  • Poehling Capital Management first reported a position in Foley Trasimene Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A in Q4 2020 and held it in 3 quarters.
  • Poehling Capital Management's Foley Trasimene Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A position peaked at $2.29M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Foley Trasimene Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A as of Q3 2021.

Based on Poehling Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.